Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Impact On Glycemic Parameters

被引：0
|
作者：
Diekmann, F. [1 ]
Tedesco-Silva, H. [2 ]
Peddi, V. [3 ]
Sanchez-Fructoso, A. [4 ]
Marder, B. [5 ]
Russ, G. [6 ]
Flynn, A. [7 ]
Hahn, C. [7 ]
Li, H. [7 ]
Tortorici, M. [7 ]
Schulman, S. [7 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Hosp Rim & Hipertensao, Sao Paulo, Brazil
[3] Calif Pacific Med Ctr, San Francisco, CA USA
[4] Hosp Clin San Carlos, Madrid, Spain
[5] Presbyterian St Lukes Med Ctr, Denver, CO USA
[6] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[7] Pfizer, Collegeville, PA USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2014年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
B969
引用
收藏
页码：540 / 541
页数：2
相关论文
共 50 条
  • [21] Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure
    Filler, G
    Womiloju, T
    Feber, J
    Lepage, N
    Christians, U
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (08) : 2005 - 2010
  • [22] Subclinical inflammation in renal transplant recipients: Impact of cyclosporin microemulsion vs tacrolimus
    Lauzurica, Ricardo
    Pastor, Mari Cruz
    Bayes, Beatriz
    Malumbres, Susana
    Homs, Mercedes
    Llopis, Maria Antonia
    Bonet, Jose
    Romero, Ramon
    TRANSPLANT INTERNATIONAL, 2007, 20 : 231 - 231
  • [23] Subclinical inflammation in renal transplant recipients: Impact of cyclosporin microemulsion vs tacrolimus
    Lauzurica, Ricardo
    Pastor, M. Cruz
    Bayes, Bety
    Malumbres, Susana
    Homs, Merche
    Llopis, M. Antonia
    Bonet, Josep
    Romero, Ramon
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 390 - 391
  • [24] Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients
    Roth, D
    Colona, J
    Burke, GW
    Ciancio, G
    Esquenazi, V
    Miller, J
    TRANSPLANTATION, 1998, 65 (02) : 248 - 252
  • [25] Tacrolimus decreases tubular phosphate wasting in renal allograft recipients
    Falkiewicz, K
    Nahaczewska, W
    Boratynska, M
    Owczarek, H
    Klinger, M
    Kaminska, D
    Wozniak, M
    Szepietowski, T
    Patrzalek, D
    TRANSPLANTATION PROCEEDINGS, 2003, 35 (06) : 2213 - 2215
  • [26] A Comparative, Randomized Trial of Concentration-Controlled Sirolimus Combined With Reduced-Dose Tacrolimus or Standard-Dose Tacrolimus in Renal Allograft Recipients
    Bechstein, W. O.
    Paczek, L.
    Wramner, L.
    Squifflet, J. -P.
    Zygmunt, A. J.
    TRANSPLANTATION PROCEEDINGS, 2013, 45 (06) : 2133 - 2140
  • [27] Pharmacogenetic vs. Concentration-Controlled Optimization of Tacrolimus Dosing in Renal Allograft Recipients
    Kuypers, D. R. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 595 - 596
  • [28] Mycophenolate mofetil vs. Sirolimus in high immunologic risk renal allograft recipients on tacrolimus-based immunosuppressive regimen with ATG induction
    Durlik, Magdalena
    Tronina, Olga
    Baczkowska, Teresa
    Klinger, Marian
    Rutkowski, Boleslaw
    Wiecek, Andrzej
    Ostrowski, Marek
    Paczek, Leszek
    Szmidt, Jacck
    Rowinski, Wojciech
    Nowaczyk, Maria
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 522 - 522
  • [29] Long-term pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients
    Kuypers, DRJ
    Claes, K
    Evenepoel, P
    Maes, B
    Vanrenterghem, Y
    THERAPEUTIC DRUG MONITORING, 2003, 25 (04) : 447 - 451
  • [30] TRANSITION FROM GENERIC TO BRAND TACROLIMUS IN TUNISIAN RENAL TRANSPLANT RECIPIENTS
    Amor, Dorra
    Wissal, Sahtout
    Ellouz, A.
    Abderrahman, Ameni
    Azzabi, Awatef
    HadjBrahim, Mayssa
    Mrabet, Sanda
    Fradi, Asma
    Ben Aicha, Narjes
    Zallema, Dorsaf
    Sabri, Ferdaous
    Omezzine, Asma
    Guedri, Yosra
    Achour, Abdeltif
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
12345